Ph 1 ADI-PEG 20 Plus Doxorubicin; Patients With HER2 Negative Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2 Negative Metastatic Breast Cancer
Interventions: DRUG: ADI-PEG 20
Sponsor: Polaris Group